ライフサイエンスコーパス: differentiation therapy

1 e, for this reason, the paradigm for 'cancer differentiation therapy'.

2 t to alter leukemia-initiating cell fate for differentiation therapy.

3 alpha regulation, unveiling a new avenue for differentiation therapy.

4 as a unique opportunity for intervention by differentiation therapy.

5 iency could be rational targets for leukemia differentiation therapy.

6 r cause of death despite the introduction of differentiation therapy.

7 teosarcoma and identify USP1 as a target for differentiation therapy.

8 ndergo cell cycle arrest, an approach termed differentiation therapy.

9 a malignancy that can be cured clinically by differentiation therapy.

10 l system for investigating the principles of differentiation therapy.

11 yeloid leukemia cells refractory to retinoid differentiation therapy.

12 al studies toward the treatment of cancer by differentiation therapy.

13 oncogenic driver and a promising target for differentiation therapy.

14 toxic chemotherapy with molecularly-targeted differentiation therapies.

15 ctivity can be modulated in the presence of 'differentiation therapy' and 'transcription therapy' age

16 reactivate PRDM1 expression as part of novel differentiation therapy approaches.

17 d healing, whereas attenuating it could be a differentiation therapy-based approach for treating psor

18 and constructs a platform towards extending differentiation therapy by performing "dry" molecular bi

19 d leukemia cells may enhance the activity of differentiation therapy drugs for this type of leukemia.

20 To establish a system to study differentiation therapy drugs, we used the androgen-inde

21 iating cells and novel targets applicable to differentiation therapies for glioblastoma.

22 Effective differentiation therapy for acute myeloid leukemia (AML)

23 This interaction is the molecular target of differentiation therapy for acute promyelocytic leukaemi

24 All-trans-retinoic acid (RA) is used as a differentiation therapy for acute promyelocytic leukemia

25 R140Q could have potential applications as a differentiation therapy for cancer.

26 rder, hold substantial clinical potential as differentiation therapy for RMS and perhaps other solid

27 ich are spurring research regarding nontoxic differentiation therapy for this disease.

28 es proof-of-principle for inducing an MET as differentiation therapy for TICs and uncovers a role for

29 The best proof of principle for differentiation therapy has been the treatment of acute

30 Since the 1970s, the concept of differentiation therapy has been viewed as a promising a

31 e exquisite sensitivity of APL to ATRA-based differentiation therapy has not been extended to other o

32 ever, the successful clinical application of differentiation therapy has only been realized since the

33 uccess of all-trans-retinoic acid (RA)-based differentiation therapy in acute promyelocytic leukemia

34 11c provided surrogate imaging biomarkers of differentiation therapy in an acute promyelocytic leukem

35 ing approaches for cell cycle inhibition and differentiation therapy in cancer.

36 gr-1 targets may provide important tools for differentiation therapy in certain leukemic phenotypes.

37 of APL, presenting a potential paradigm for differentiation therapy in clinical oncology.

38 gnaling by PORCN inhibition holds promise as differentiation therapy in genetically defined human can

39 C3 function represent a promising option for differentiation therapy in malignant tumors with dysregu

40 area of interest is chromatin remodeling and differentiation therapy, including agents such as all- r

41 Theoretically, the concept of differentiation therapy involves turning a cancer cell "

42 Differentiation therapy is an area of oncology that is i

43 Differentiation therapy is being developed as an additio

44 btraction hybridization was combined with a "differentiation therapy" model of cancer in which human

45 ered clinical trials as a potential drug for differentiation therapy of advanced prostate cancer.

46 Advances in differentiation therapy of cancer are likely to depend o

47 APL has overnight become a paradigm for the differentiation therapy of cancer.

48 factors support the continued enthusiasm for differentiation therapy of leukemia in the future.

49 supraphysiological levels of this hormone in differentiation therapy of leukemic cells.

50 onse in keratinocytes, with implications for differentiation therapy of squamous cancer.

51 ddition of specific antiangiogenic agents to differentiation therapy or chemotherapy should be explor

52 This differentiation therapy propelled interest in uncovering

53 by blocking Cyp26a1 in cell replacement/ESC differentiation therapy to treat neurodegenerative disea

54 ting certain genes and pathways involved in "differentiation therapy" used in the treatment of acute

55 The potential therapeutic utility of HDACi differentiation therapy was established in three differe

56 atically to all-trans retinoic acid mediated differentiation therapy, whereas others do not.

57 a hormone ligand is required for its action, differentiation therapy with ATRA may be self-limiting.